Výsledky vyhledávání - "Vania Estanek"

Abstract 1161: EZH2 inhibitor tazemetostat demonstrates activity in preclinical models of Bruton's tyrosine kinase inhibitor-resistant relapsed/refractory mantle cell lymphoma

Autor: Jeremy C. Cunniff, Alejandra Raimondi, Crag Markwood, Weiqing Chen, Cuyue Tang, Arleide Lee, Revonda Mehovic, Veronica Gibaja, Vania Estanek, Daniel T. Dransfield, Jeffrey A. Keats

Publikováno v: Cancer Research. 81:1161-1161

Tazemetostat (EZM6438) is a potent, orally bioavailable small molecule inhibitor of EZH2, the enzymatic subunit of the polycomb repressive complex 2, which has been approved for treatment of epithelioid sarcoma and relapsed/refractory follicular lymp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5ef5d73cd93a0b173b274936d18d6713
https://doi.org/10.1158/1538-7445.am2021-1161

Zobrazit plný text záznamu

Abstract B011: Synergistic activity of tazemetostat in combination with androgen signaling inhibitors in preclinical models of prostate cancer demonstrates potential for clinical expansion

Autor: Daniel T. Dransfield, Dorothy Brach, Jeffrey A. Keats, Alejandra Raimondi, Chloe Pantano, Vinny Motwani, Vania Estanek

Publikováno v: Molecular Cancer Therapeutics. 18:B011-B011

Prostate cancer (PCa) is the second leading cause of cancer death among men in the United States. Current available treatments include chemical castration and therapies targeting androgen receptor (AR) signaling pathways. Although initial responses a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d48ab9476ce5465205a82275c84d4040
https://doi.org/10.1158/1535-7163.targ-19-b011

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání